Zynlonta comprises an antibody specific for CD19 conjugated via a VA linker to the DNA alkylating agent SG3199 and it was approved for treating B-cell non-Hodgkin lymphoma, over-expressing CD19. The gene discussed is CD19; the disease is B-cell non-Hodgkin lymphoma.